# PREVENTING CHRONIC DISEASE PUBLIC HEALTH RESEARCH, PRACTICE, AND POLICY 

# Simulating and Evaluating Local Interventions to Improve Cardiovascular Health 

Jack Homer, PhD; Bobby Milstein, PhD, MPH; Kristina Wile, MS; Justin Trogdon, PhD; Philip Huang, MD, MPH; Darwin Labarthe, MD, MPH, PhD; Diane Orenstein, PhD


#### Abstract

Suggested citation for this article: Homer J, Milstein B, Wile K, Trogdon J, Huang P, Labarthe D, et al. Simulating and evaluating local interventions to improve cardiovascular health. Prev Chronic Dis 2010;7(1). http://www.cdc. gov/pcd/issues/2010/jan/08_0231.htm. Accessed [date].


PEER REVIEWED


#### Abstract

Numerous local interventions for cardiovascular disease are available, but resources to deliver them are limited. Identifying the most effective interventions is challenging because cardiovascular risks develop through causal pathways and gradual accumulations that defy simple calculation. We created a simulation model for evaluating multiple approaches to preventing and managing cardiovascular risks. The model incorporates data from many sources to represent all US adults who have never had a cardiovascular event. It simulates trajectories for the leading direct and indirect risk factors from 1990 to 2040 and evaluates 19 interventions. The main outcomes are first-time cardiovascular events and consequent deaths, as well as total consequence costs, which combine medical expenditures and productivity costs associated with cardiovascular events and risk factors. We used sensitivity analyses to examine the significance of uncertain parameters. A base case scenario shows that population turnover and aging strongly influence the future trajectories of several risk factors. At least 15 of 19 interventions are potentially cost saving and could reduce deaths from first cardiovascular events by approximately $20 \%$ and total consequence costs by $26 \%$. Some interventions act quickly


to reduce deaths, while others more gradually reduce costs related to risk factors. Although the model is still evolving, the simulated experiments reported here can inform policy and spending decisions.

## Introduction

Conditions in particular neighborhoods or cities can profoundly enhance or impede people's prospects for a healthy life (1). This dependence on local context is especially evident in cardiovascular health, for which behavioral, social, and environmental factors combine to affect the likelihood of developing disease or dying prematurely (2). Heart disease and stroke are largely preventable, but they remain the first and third leading causes of death in the United States, partly because we have yet to establish living conditions that minimize such modifiable risks as smoking, obesity, stress, air pollution, poor diet, and physical inactivity. The importance of intervening to limit these risks is highlighted in A Public Health Action Plan to Prevent Heart Disease and Stroke (3).

The notion that cardiovascular disease (CVD) can be prevented through local actions raises practical questions that can be examined through systems modeling and simulation. Working closely with colleagues in Austin/Travis County, Texas, and subject matter experts at the Centers for Disease Control and Prevention and the National Institutes of Health, we developed a system dynamics simulation model to answer the following questions:

- How does local context affect the major risk factors for CVD and, in turn, population health status and costs?

[^0]- How might local interventions affect CVD risk, health status, and costs over time?
- How might local health leaders better balance their policy efforts given limited resources?


## Methods

System dynamics models improve our ability to anticipate the likely effects of interventions in dynamically complex situations, where the pathways from interventions to outcomes may be indirect, delayed, and possibly affected by nonlinearities or feedback loops (4). System dynamics has been used effectively since the 1970s to
model many areas of public health and social policy, including CVD (5).

## Model structure

We previously described a framework for understanding cardiovascular health in a local context (6). That framework has been refined and quantified by using additional literature and input from veteran health planners and analysts. The resulting simulation model (Figure 1) focuses on primary prevention; it does not address people who have experienced a CVD event. Causal influences move down and to the right, ending with 2 outcomes: 1) firsttime cardiovascular events and consequent deaths and 2)


Figure 1. Simulation model for cardiovascular disease (CVD) outcomes. This diagram depicts major health conditions related to CVD and their causes. Boxes identify risk factor prevalence rates modeled as dynamic stocks. The population flows associated with these stocks - including people entering the adult population, entering the next age category, immigration, risk factor incidence, recovery, cardiovascular event survival, and death - are not shown.

## Key:

Blue solid arrows: causal linkages affecting risk factors and cardiovascular events and deaths.
Brown dashed arrows: influences on costs.
Purple italics: factors amenable to direct intervention.
Black italics (population aging, cardiovascular event fatality): other specified trends.
Black nonitalics: all other variables, affected by italicized variables and by each other.

[^1]costs associated with these events and with the identified risk factors.

The model starts with conditions in the United States in 1990 and simulates them continuously through 2040. The population without CVD and risk factor prevalence rates are represented as dynamic stock or state variables, subdivided by sex and age group (18-29 y, 30-64 y, and $\geq 65 \mathrm{y}$ ). Smoking and obesity are viewed as reversible conditions, whereas diabetes, high blood pressure, and high cholesterol are viewed as chronic conditions that are not reversible but that can be controlled, with the help of good-quality primary health care, to reduce CVD risk.

The incidence of first-time CVD events in the model is driven by the effect of several direct risk factors, based on a widely used risk calculator from the Framingham Heart Study (7). We modified that calculator in several ways for this study, most fundamentally by estimating annual risks at a population level on the basis of risk factor prevalence rates, rather than at the level of an individual. (A detailed description of the modified calculator is available at http://sustainer.org/cvd/documents/SELI_App1. pdf). We also recognized the direct effect on CVD events, especially myocardial infarctions, from secondhand smoke and small particulate matter (PM 2.5) air pollution (8-11). Furthermore, because deaths from CVD have declined partly because of improvements in emergency and acute care, we incorporated a downward trend in the CVD casefatality rate for 1990 through 2003 (12).

Obesity contributes to CVD, largely through diabetes, high blood pressure, and high cholesterol levels (13). Other indirect influences in the model are physical inactivity, poor diet, psychosocial stress, and smoking as it affects diabetes and obesity (14-21).

Both the direct and indirect influences in the model may be modified by 19 interventions (Table 1). These 19 interventions could be implemented at a city, county, or state level rather than requiring changes nationwide. In functional terms, the interventions are of a few basic types: those that provide broader access to health-promoting services, those that promote desirable behaviors, and those that tax or regulate to deter undesirable behaviors.

## Cost calculation

We used a common metric - constant 2005 dollars — to
track medical and productivity costs (for morbidity and mortality) that might be affected by the 19 interventions. We measured the societal value of morbidity (sick days) and premature mortality (years of life lost) using a human capital approach, which estimates the market value of lost productivity at work and at home (22). (A detailed description of cost calculations is available at http://sustainer.org/ cvd/documents/SELI_App2.pdf.) This summary of medical and productivity costs can determine whether any intervention, or package of interventions, is justified by its likely aggregate consequences, or "total consequence costs." We did not estimate the costs of interventions. However, the total consequence costs can inform spending decisions. For example, suppose that for a given intervention the model calculates a total consequence cost savings of $\$ 50$ per capita. Planners may then conclude that up to $\$ 50$ per capita could be justifiably spent to implement that intervention and still create positive net benefits to society.

The model tracks 3 types of intervention consequences:

- Medical and productivity costs attributable to fatal and nonfatal CVD events.
- Medical and productivity costs attributable to noncardiovascular complications of smoking (eg, lung cancer), diabetes (eg, blindness), high blood pressure (eg, kidney failure), and obesity (eg, colorectal cancer). We have thus far been able to quantify these costs, but not yet the costs related to noncardiovascular complications of stress (eg, depression), physical inactivity (eg, back pain), or poor diet (eg, colorectal cancer).
- Costs of services and products to manage risk factors. These include medications and visits for managing chronic disorders, mental health services, weight-loss services, and smoking cessation services and products.


## Model calibration

Although the model is meant to investigate interventions in localities such as Austin/Travis County, we began by calibrating it to represent the entire United States. This approach enabled more precise estimation, given that certain data were either unreliable or unavailable at the local level. The results are generally reported as per capita estimates to facilitate interpretation at a local level. Table 2 lists the major information sources on which the model is based (23-32).

The model specifies initial (1990) incidence rates for

[^2]smoking, obesity, diabetes, high blood pressure, and high cholesterol, as well as cessation rates for smoking and obesity. These parameters have been set so that the model accurately simulates the observed changes in prevalence rates in the National Health and Nutrition Examination Survey from 1988-1994 to 1999-2004.

The model also contains 56 causal links requiring the estimation of relative risks, effect sizes, or initial values. Many of these parameters were estimated through the use of published studies, meta-analyses, and in some instances, ad hoc surveys of veteran practitioners (33). Because most of these parameter estimates have some level of uncertainty, we also identified lower and upper bounds to be used for sensitivity analysis.

## Model testing

Having calibrated the model to accurately reproduce observed trends in risk factor prevalence rates as well as CVD events and deaths, we then explored plausible futures. A base case scenario assumed no changes after 2004 in many of the local determinants of risk in the adult population, including healthiness of diet, extent of physical activity, stress, use of quality primary care, air pollution, and the prevalence rates of smoking and obesity among incoming 18 -year-olds. This base case should not be taken as a statement about what is most likely to happen in the absence of intervention, but rather serves as a straightforward and easily understood benchmark against which to compare intervention scenarios.

We tested interventions singly and in groups of similar interventions. For all interventions, we assumed a 1-year ramp-up during 2009, followed by full implementation from 2010 through 2040. The significance of full implementation depends on the intervention, but in all cases is based on effect sizes that the research literature or veteran practitioners indicate should be possible:

- For the 7 marketing interventions and for taxes on tobacco or junk food: doing the maximum that has been demonstrated or seriously proposed somewhere in the United States.
- For the 6 access interventions: raising access to $100 \%$.
- For smoking restriction: reducing secondhand exposures in workplaces and public places to zero.
- For air pollution: reducing small particulate matter by 50\% from its 2001-2003 value.
- For sources of chronic stress: a $50 \%$ reduction.
- For the quality of primary care (ie, adherence to guidelines): improvement from a national average of $54 \%$ (27) to $75 \%$.

For each intervention scenario, we conducted separate simulations using the midpoint, lower-end, and upper-end values for all uncertain parameters. This method yielded a range of plausible outcomes for each intervention scenario.

## Discussion

## Base case results

The base case projects that even after 2004, when we assume no further changes to the model's inputs, historical trends in the model's risk factor prevalence rates will continue through 2040, although with diminishing slopes. In particular, the model projects further declines in smoking (and, thus, secondhand smoke exposure) and high cholesterol, and at the same time further growth in high blood pressure and diabetes. The projected continuation of past trends reflects the eventual death of older cohorts and their replacement by younger cohorts with different habits and characteristics. For instance, the continued decline of smoking prevalence reflects the lower rate of smoking among teens and young adults today than in previous decades. Such demographic turnover also helps explain the continued growth of high blood pressure and diabetes, which occurs in the model as a legacy of the increase in obesity - a leading risk factor for both disorders - from 1980 to 2004 . The projected continuation of trends also reflects the future aging of the population; the over-65 population will increase from 2010 through 2030. This aging effect contributes to the projected decline in smoking because smoking is much less common among the elderly. It also contributes to the projected increase in high blood pressure and diabetes because the prevalence of these disorders is higher with increasing age.

Deaths from first-time CVD events, which declined by $35 \%$ from 1990 to 2004, are projected in the base case to rebound by $33 \%$ from 2004 to 2040. Much of the past decline is attributable to a $28 \%$ reduction in the event fatality rate, from improvements in emergency and acute care. But it also reflects an $11 \%$ decline in the rate of CVD events that occurred, despite increases in high blood pressure and diabetes, because of decreases in smoking,

[^3]secondhand smoke, PM 2.5 air pollution, and uncontrolled high cholesterol.

The potential future rebound in deaths anticipated by our model reflects a $17 \%$ increase in fatality from CVD events per capita and a $15 \%$ increase in the rate of CVD events because of the aging of the population. Although the base case projects no future increase in CVD events or deaths within each age group, the aging of the population will lead to an increase in the overall rate of CVD events and deaths.

Per capita total consequence costs, which the model calculates to have declined by $25 \%$ from 1990 to 2004, are projected in the base case to decline by another $5 \%$ from 2004 to 2040. Total consequence costs encompass not only CVD events (which account for $44 \%$ of the total costs in 2004) but also noncardiovascular complications of risk factors (also $44 \%$ ) and management of risk factors ( $12 \%$ ). Although per capita CVD event costs are projected to increase by $12 \%$ from 2004 to 2040 (reflecting the increase in the frequency of the events themselves) and per capita risk management costs are projected to increase by $8 \%$ (reflecting the growing demand for blood pressure and diabetes treatment), these increases are more than offset by a $25 \%$ decrease in noncardiovascular complications. This decrease is due to the projected decline of smoking, which in 2004 was responsible for more than 400,000 noncardiovascular deaths, primarily from lung cancer and chronic obstructive pulmonary disease. These premature non-CVD deaths from smoking account for a large fraction (about $28 \%$ in 2004) of the total consequence costs calculated in the model.

## Intervention scenario results

Individual tests of the 19 interventions suggest that each can reduce deaths from first-time CVD events, and most can reduce total consequence costs. Four of the interventions, however, raise total consequence costs, meaning that they increase risk factor management costs more than they decrease the costs of medical events and complications. These 4 interventions include the 2 that encourage use of mental health services and the 2 that encourage use of weight-loss services. However, because of limitations in the model, planners should not dismiss these interventions in the real world. In the case of mental health services, we have not yet estimated the noncardiovascular costs of depression. In the case of weight-loss
services for obese people, our estimates of cost and benefit are based on conventional dieting and exercise programs, rather than on bariatric surgery, which, although more costly, also appears to be more effective (34).

We present simulation results for only the 15 interventions that in the model do not increase total consequence costs (Figure 2). Such a multipronged approach may be challenging to implement, given resource limitations, but it is useful to look at what could be achieved.

The model suggests that if all risk factors in the model were eliminated, the death rate could be reduced by approximately $60 \%$ below the base case, which falls between the $50 \%$ to $75 \%$ rate that other authors have suggested (35). This model dichotomizes blood pressure, cholesterol, and diabetes as "high" or "not high" and does not further subdivide the "not high" into normal and borderline. Reducing borderline conditions (prehypertension, borderline cholesterol, prediabetes) to normal could further reduce CVD, but we cannot explore this possibility with this model. (A static analysis of the potential benefits of reducing both high and borderline conditions is available at http://sustainer.org/cvd/documents/SELI_App3.pdf.)

The model projects that a 15 -component intervention could reduce the first-time CVD event death rate relative to the base case by $20 \%$ (range based on sensitivity analysis, $15 \%-26 \%$ ) in 2015 and by 19\% (range, 14\%-25\%) in 2040. Thus, the interventions that could reduce CVD deaths have a relatively rapid effect.

The effect of the interventions is more gradual with regard to total consequence costs than it is with regard to CVD deaths; nearly $40 \%$ of the eventual effect on costs occurs after 2015 (Figure 2). If all risk factors in the model were eliminated, consequence costs could be reduced by approximately $80 \%$ below the base case. Relative to the base run, the 15 -component intervention reduces consequence costs by $16 \%$ (range, $12 \%-23 \%$ ) in 2015, eventually reaching $26 \%$ (range, $19 \%$ - $33 \%$ ) in 2040. The reduction in consequence costs is $\$ 348$ per capita (range, $\$ 254-\$ 514$ ) in 2015 and $\$ 565$ per capita (range, $\$ 416-\$ 722)$ in 2040.

The 15 -component intervention may be better understood by examining the incremental contributions of its components grouped by topical cluster (Figure 3). We used the same base case graph as in Figure 2 and then incre-

[^4]

Figure 2. Estimated impacts of a 15-component intervention, with ranges based on sensitivity testing, simulation model for cardiovascular disease (CVD) outcomes. The 15 interventions are listed in Table 1 under the topical clusters of Care, Air, and Lifestyle.

## Key:

Blue line = base case results.
Black line = expected reduction in death rate or costs from the 15 -component intervention when the uncertain parameters are all set to their baseline values. Orange shaded area around the black line = envelope of plausible outcomes in the 15-component intervention outcomes based on sensitivity testing. Upper edge (least impact) results when all uncertain impact parameters are set to their lowest values, while lower edge (most impact) results when all uncertain impact parameters are set to their greatest values.
Gray line = the model's calculation of what the death rate or costs would be if all of the risk factors in the model - smoking, small particulate matter (PM 2.5) air pollution, high blood pressure, high cholesterol, diabetes, obesity, poor nutrition, inactivity, and stress - were reduced to zero.
mentally added the following topical clusters:

1) The 3 interventions that improve the use and quality of primary care (Care).
2) The 6 interventions related to air quality and smoking (Air).
3) The 5 interventions related to improved nutrition and physical activity and the 1 intervention that would reduce sources of stress (Lifestyle).

The relative effects of the clusters are different for CVD deaths than they are for total consequence costs. Of the 3 topical clusters, the largest contributor to projected reductions in CVD deaths, both in 2015 and 2040, is Care, followed by Air and then a smaller (though growing) contribution from Lifestyle. In contrast, the largest contributor to projected cost reductions, both in 2015 and 2040, is Air, followed by Lifestyle and then a smaller (and ultimately negligible) contribution from Care. The contributions to per capita cost reduction in 2015 are $\$ 235$ from Air, $\$ 71$ from Lifestyle, and $\$ 42$ from Care. The contributions in 2040 are $\$ 393$ from Air, $\$ 165$ from Lifestyle, and $\$ 7$ from Care.

## Conclusions

The major factors that affect cardiovascular health at
a population level interact through causal pathways and develop through gradual accumulations that defy simple calculation. This dynamic complexity - and not just gaps in data - is a challenge for local leaders who want to intervene most effectively given limited resources. Our simulation model helps meet this challenge by integrating what is known about the various risk factors in a single testable framework for prospective policy analysis.

The simulations reported here point to several conclusions that local leaders and national allies may find valuable.

1) The CVD death rate has declined in recent years, not only because of improvements in emergency and acute care but also because of reductions in the CVD event rate itself, due to reductions in smoking, secondhand smoke, particulate air pollution, and uncontrolled high cholesterol. If this progress does not continue at a similar pace in the future, however, the CVD death rate will likely rebound strongly as the population ages.
2) Medical and productivity costs associated with CVD risk factors have declined because of declines in firsttime CVD events and consequent deaths, and because of reductions in non-CVD deaths (especially lung cancer and chronic obstructive pulmonary disease) associated with

[^5]

Figure 3. Projected changes in the death rate from first-time cardiovascular disease (CVD) events and in total consequence costs per capita when 15 interventions are combined, expressed in terms of clusters of interventions, simulation model for cardiovascular health outcomes.

## Key:

Blue line = base case results.
Gray line = outcomes if all risk factors were reduced to zero.
Red line = implement the 3 interventions that improve the use and quality of primary care (Care).
Green line = add the 6 interventions related to air quality and smoking (Air).
Black line = add the 5 interventions related to improved nutrition and physical activity and the 1 intervention that would reduce sources of stress (Lifestyle). This scenario includes all 15 interventions and is identical to the black line in Figure 2.
smoking. Population aging will likely keep smoking prevalence on a path of decline into the future, so that even if CVD deaths rebound, the total consequence costs need not rebound.
3) Of 19 interventions that local planners may consider for lowering CVD risk, at least 15 could reduce CVD deaths without increasing total consequence costs.
4) Interventions aimed at reducing smoking and improving indoor and outdoor air quality can save lives relatively quickly and can justify intervention spending equivalent to as much as $\$ 300$ per capita per year for 30 years (in 2005 constant dollars, without time discounting) to achieve the full implementation targets. Most local health leaders are already aware of the need for tobacco control and smoking bans, but many may not be aware of the contribution of particulate air pollution to CVD risk, even in areas like Austin/Travis County without heavy pollution.
5) Interventions aimed at improving the use and quality of primary care to diagnose and control high blood pressure, high cholesterol, and diabetes can save lives quickly but should not be expected to save much on total costs, primarily because of the high cost of medications. Consequently, the intervention spending to achieve and maintain such improvement should not exceed the
equivalent of $\$ 25$ per capita per year for 30 years. Other researchers have similarly found that good preventive care for chronic conditions may be cost-effective but is not necessarily cost-saving $(36,37)$.
6) Interventions to improve nutrition and physical activity and to reduce sources of stress take more time to affect CVD deaths, as they gradually reduce obesity and other chronic disorders. Nonetheless, their contribution grows over time and may justify intervention spending equivalent to as much as $\$ 100$ per capita per year for 30 years.

The ability of particular localities to achieve full implementation within these cost limits may vary depending on context and implementation factors. Potential extensions and improvements to the model include the following:

- Modeling medical and personal costs for the post-CVD event population and targeted interventions for secondary prevention to reduce the rate of recurrent CVD events.
- Modeling the prevalence rates of borderline conditions (prehypertension, borderline cholesterol, prediabetes) and incorporating them in the CVD risk calculations.
- Modeling the prevalence of former smokers and incorporating their differential risks in the CVD event and cost calculations.

[^6]- Incorporating the non-CVD consequences of stress, physical inactivity, and poor diet.
- Estimating intervention implementation costs to better inform intervention priorities.
- Incorporating additional independent risk factors for CVD (eg, excess sodium intake, excess trans fat intake, vitamin D deficiency, periodontal disease).

The model described here was created through a close collaboration with health planners in Austin/Travis County, who are now using a locally calibrated version of the model to support local strategy design and leadership development. We plan to pursue similar engagements with colleagues elsewhere. With more widespread use, this tool may help health planners across the country transform local contexts to most effectively improve cardiovascular health.

## Acknowledgments

We acknowledge the contributions of Terry Pechacek, Dave Buchner, Roseanne Farris, Parakash Pratibhu, Deb Galuska, Adolfo Valadez, Karina Loyo, Rick Schwertfeger, Cindy Batcher, Ella Pugo, Jessie Patton-Levine, Josh Vest, Patty Mabry, John Robitscher, Alyssa Easton, Nancy Williams, and Larry Fine.

## Author Information

Corresponding Author: Jack Homer, PhD, Homer Consulting, 4016 Hermitage Dr, Voorhees, NJ 08043. Telephone: 856-810-7673. E-mail: jhomer@comcast.net.

Author Affiliations: Bobby Milstein, Darwin Labarthe, Diane Orenstein, Centers for Disease Control and Prevention, Atlanta, Georgia; Kristina Wile, Sustainability Institute, Stow, Massachusetts; Justin Trogdon, RTI International, Research Triangle Park, North Carolina; Philip Huang, Austin/Travis County Health and Human Services Department, Austin, Texas.

## References

1. Bell J, Rubin V. Why place matters: building a movement for healthy communities. Oakland (CA): PolicyLink; 2007.
2. Labarthe D. Epidemiology and prevention of cardiovascular diseases: a global challenge. Gaithersburg (MD): Aspen Publishers; 1998.
3. A public health action plan to prevent heart disease and stroke. Centers for Disease Control and Prevention; 2003. http://www.cdc.gov/dhdsp/library/ action_plan/. Accessed August 14, 2009.
4. Sterman JD. Business dynamics: systems thinking and modeling for a complex world. Boston (MA): Irwin McGraw-Hill; 2000.
5. Homer JB, Hirsch GB. System dynamics modeling for public health: background and opportunities. Am J Public Health 2006;96(3):452-8.
6. Homer J, Milstein B, Wile K, Pratibhu P, Farris R, Orenstein D. Modeling the local dynamics of cardiovascular health: risk factors, context, and capacity. Prev Chronic Dis 2008;5(2). http://www.cdc.gov/pcd/ issues/2008/apr/07_0230.htm. Accessed August 14, 2009.
7. Anderson KM, Odell PM, Wilson PW, Kannel WB. Cardiovascular disease risk profiles. Am Heart J 1991;121(1 Pt 2):293-8.
8. Pope CA 3rd, Burnett RT, Thurston GD, Thun MJ, Calle EE, Krewski D, et al. Cardiovascular mortality and long-term exposure to particulate air pollution: epidemiological evidence of general pathophysiological pathways of disease. Circulation 2004;109(1):71-7.
9. Dominici F, Peng RD, Zeger SL, White RH, Samet JM. Particulate air pollution and mortality in the United States: did the risks change from 1987 to 2000? Am J Epidemiol 2007;166(8):880-8.
10. Mowery PD, Babb S, Bishop EE, Pechacek TF. Comparison of two methods for estimating prevalence of exposure to secondhand smoke in the US population. Paper presented at Towards a Smokefree Society Conference; September 9-12, 2007; Edinburgh, Scotland.
11. The health consequences of involuntary exposure to tobacco smoke: a report of the Surgeon General. US Department of Health and Human Services, Public Health Service; 2006. http://www.surgeongeneral.gov/ library/secondhandsmoke/. Accessed August 14, 2009.
12. Morbidity and mortality: chart book on cardiovascular, lung, and blood diseases. National Heart, Lung, and Blood Institute; 2007. http://www.nhlbi.nih.gov/ resources/docs/cht-book.htm. Accessed August 14, 2009.
13. Thompson D, Edelsberg J, Colditz GA, Bird AP, Oster G. Lifetime health and economic consequences of obe-

[^7]sity. Arch Intern Med 1999;159(18):2177-83.
14. Katzmarzyk PT, Gledhill N, Shephard RJ. The economic burden of physical inactivity in Canada. CMAJ 2000;163(11):1435-40.
15. Fleshner M. Physical activity and stress resistance: sympathetic nervous system adaptations prevent stress-induced immunosuppression. Exerc Sport Sci Rev 2005;33(3):120-6.
16. Elmer PJ, Obarzanek E, Vollmer WM, Simons-Morton D, Stevens VJ, Young DR, et al. Effects of comprehensive lifestyle modification on diet, weight, physical fitness, and blood pressure control: 18-month results of a randomized trial. Ann Intern Med 2006;144(7):48595.
17. Rozanski A, Blumenthal JA, Kaplan J. Impact of psychological factors on the pathogenesis of cardiovascular disease and implications for therapy. Circulation 1999;99(16):2192-217.
18. Björntorp P. Do stress reactions cause abdominal obesity and comorbidities? Obes Rev 2001;2(2):73-86.
19. Kouvonen A, Kivimaki M, Virtanen M, Pentti J, Vahtera J. Work stress, smoking status, and smoking intensity: an observational study of 46,190 employees. J Epidemiol Community Health 2005;59(1):63-9.
20. Willi C, Bodenmann P, Ghali WA, Faris PD, Cornuz J. Active smoking and the risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 2007;298(22):2654-64.
21. Flegal KM. The effects of changes in smoking prevalence on obesity prevalence in the United States. Am J Public Health 2007;97(8):1510-4.
22. Haddix AC, Teutsch SM, Corso PS. Prevention effectiveness: a guide to decision analysis and economic evaluation. 2nd edition. New York (NY): Oxford University Press; 2003.
23. Thom T, Haase N, Rosamond W, Howard VJ, Rumsfeld J, Manolio T, et al. Heart disease and stroke statistics - 2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2006;113(6):e85-151.
24. Mendez D, Warner KE, Courant PN. Has smoking cessation ceased? Expected trends in the prevalence of smoking in the United States. Am J Epidemiol 1998;148:249-58.
25. Sloan FA, Ostermann J, Conover C, Taylor Jr DH, Picone G. The price of smoking. Cambridge (MA): MIT Press; 2004.
26. Homer J, Milstein B, Dietz W, Buchner D, Majestic E. Obesity population dynamics: exploring historical
growth and plausible futures in the US. Paper presented at 24th International System Dynamics Conference; July 23-27, 2006; Nijmegen, The Netherlands.
27. Asch SM, Kerr EA, Keesey J, Adams JL, Setodji CM, Malik S, et al. Who is at greatest risk for receiving poor-quality health care? New Engl J Med 2006;354(11):1147-56.
28. Russell MW, Huse DM, Drowns S, Hamel EC, Hartz SC. Direct medical costs of coronary artery disease in the United States. Am J Cardiol 1998;81(9):1110-5.
29. Sasser AC, Rousculp MD, Birnbaum HG, Oster EF, Lufkin E, Mallet D. Economic burden of osteoporosis, breast cancer, and cardiovascular disease among postmenopausal women in an employed population. Womens Health Issues 2005;15(3):97-108.
30. Flegal KM, Graubard BI, Williamson DF, Gail MH. Cause-specific excess deaths associated with underweight, overweight, and obesity. JAMA 2007;298(17):2028-37.
31. American Diabetes Association. Economic costs of diabetes in the US in 2002. Diabetes Care 2003;26:91732.
32. Clausen J, Jensen G. Blood pressure and mortality: an epidemiological survey with 10 years follow-up. J Hum Hypertens 1992;6:53-9.
33. Homer J. A dynamic model of cardiovascular risk: reference guide for model version 8m. Atlanta (GA): Centers for Disease Control and Prevention; 2008.
34. Sjostrom L, Lindroos AK, Peltonen M, Torgerson J, Bouchard C, Carlsson B, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 2004;351(26):2683-93.
35. Magnus P, Beaglehole R. The real contribution of the major risk factors to the coronary epidemics: time to end the "only-50\%" myth. Arch Intern Med 2001;161(22):2657-60.
36. Russell LB. Preventing chronic disease: an important investment, but don't count on cost savings. Health Aff (Millwood) 2009;18(1):42-5.
37. Kahn R, Robertson RM, Smith R, Eddy D. The impact of prevention on reducing the burden of cardiovascular disease. Circulation 2008;118(5):576-85.

[^8]
## Tables

Table 1. Interventions Used in Simulation Model for Cardiovascular Health Outcomes, Organized by Topical Cluster

| Topical Cluster |  |
| :--- | :--- |
| Care | Access to affordable primary care <br> Promotion of primary care use <br> Good-quality primary care |
| Air | Tobacco taxes and sales restrictions <br> Social marketing against smoking <br> Access to affordable smoking cessation services and products <br> Promotion of smoking cessation <br> Bans on smoking in public places <br> Regulations and incentives that reduce air pollution |
| Lifestyle | Access to affordable healthy foods <br> Promotion of healthy diet <br> Junk food taxes and sales restrictions <br> Access to safe and affordable physical activity <br> Promotion of physical activity <br> Reduced sources of chronic stress through improved living conditions and social supports |
| Weight-loss and mental health |  |
| services | Access to affordable weight-loss services for the obese <br> Promotion of weight-loss services <br> Access to affordable mental health services for the chronically stressed <br> Promotion of mental health services |

[^9]Table 2. Information Sources Used in Simulation Model for Cardiovascular Health Outcomes

| Topic | Source |
| :--- | :--- |
| Population size, growth, and aging, and health care coverage | US Census |
| Rates of cardiovascular events and deaths | Reports from American Heart Association (23) and National Institutes of Health <br> $(12)$ |
| Prevalence rates of smoking, obesity, and chronic disorders, and rates <br> of diagnosis and control of chronic disorders | National Health and Nutrition Examination Survey (NHANES), 1988-1994 and <br> $1999-2004$ |
| Fraction of 18-year-olds who smoke, are obese, or have chronic disor- <br> ders | NHANES, Youth Risk Behavior Surveillance System |
| Prevalence of psychosocial stress | Behavioral Risk Factor Surveillance System (BRFSS) |
| Access to and use of good nutrition, physical activity, and primary care | BRFSS |
| Rates of smoking cessation | Mendez et al (24), Sloan et al (25) |
| Rates of people moving from obese to nonobese | Homer et al (26) |
| Trend in fraction of workplaces allowing smoking | Surgeon General's report (11) |
| Trend in small particulate matter (PM 2.5) air pollution | Dominici et al (9) |
| Average quality of primary care | Asch et al (27) |
| Medical costs, sick days, and years of life lost due to CVD events and <br> deaths | Social Security actuarial life tables, Haddix et al (22), Russell et al (28), Sasser <br> et al (29) |
| Noncardiovascular medical costs and sick days due to smoking, obe- <br> sity, diabetes, and high blood pressure | Linked files of Medical Examination Panel Survey, National Health Interview <br> Survey |
| Noncardiovascular mortality and years of life lost due to smoking, obe- <br> sity, diabetes, and high blood pressure | Centers for Disease Control and Prevention Smoking-Attributable Mortality, <br> Morbidity, and Economic Costs (SAMMEC), World Health Organization Statistical <br> Information System, Flegal et al (30), American Diabetes Association (31), <br> Clausen et al (32) |

[^10]
[^0]:    The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the US Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.

[^1]:    The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the US Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.

[^2]:    The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the US Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.

[^3]:    The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the US Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.

[^4]:     Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.

[^5]:    The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the US Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.

[^6]:    
     does not imply endorsement by any of the groups named above.

[^7]:     Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.

[^8]:    The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the US Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.

[^9]:    The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the US Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.

[^10]:    The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the US Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.

